Drug Database
HY

hyaluronic acid (BioHy / Euflexxa / BioLon)

✓ Approved

Johnson & Johnson Services, Inc. · therapeutic agent

What is hyaluronic acid?

hyaluronic acid is a therapeutic agent developed by Johnson & Johnson Services, Inc.. It is approved for therapeutic indications via injectable (others) or intraarticular injection.

Drug Profile

Brand NamesBioHy, Euflexxa, BioLon
CompanyJohnson & Johnson Services, Inc.
RouteInjectable (Others), Intraarticular Injection
StatusApproved
Sources: ClinicalTrials.gov, Johnson & Johnson Services, Inc.

Therapeutic Indications

hyaluronic acid is developed for 4 unique indications across 3 therapeutic areas.

Therapeutic AreaConditionPhase
Eye disordersGlaucoma✓ Approved
Musculoskeletal and connective tissue disordersOsteoarthritis✓ Approved
Surgical and medical proceduresAdjuvant therapy✓ Approved
Eye disordersDry eyePhase II

Related Research Articles

PubMedInternational journal of biological macromolecules2026-05-24

Bone matrix-mimetic DLP-printable gelatin and hyaluronic acid nanocomposite hydrogels for cranial defect repair.

Chi Bowen B, Yu Fenglin F, Chen Weiqi W, Jiang Lingling L et al.

Cranial defect repair remains a major clinical challenge due to limited bone regenerative capacity and the need to preserve the adjacent neural microenvironment. Here, we developed a digital light processing printable biomimetic hydrogel scaffold based on gelatin methacrylate (GelMA), hyaluronic acid methacrylate (HAMA), and nano-hydroxyapatite (nHA), designed to recapitulate the organic-inorganic structure of native bone. The scaffold exhibited favorable printability, mechanical properties, and controlled swelling-degradation behavior. In vitro, it significantly enhanced cell proliferation and osteogenic differentiation. In a rat cranial defect model, the scaffold supported scaffold-associated tissue ingrowth, collagen-rich matrix remodeling, early vascularization, and apparent radiopaque defect filling, while showing acceptable compatibility with the adjacent cortical tissue. Transcriptomic and metabolomic analyses suggested coordinated changes in extracellular matrix (ECM) remodeling, angiogenesis, immune regulation, and metabolism-related remodeling. In addition, sustained release of Ca2+ and phosphate ions may provide bioactive cues that support osteogenic differentiation and microenvironmental regulation. Overall, these findings indicate that the GelMA/HAMA/nHA scaffold may serve as a structurally supportive and bioactive platform for cranial defect repair.

PMID 42176926
Read full article →
PubMedInternational journal of biological macromolecules2026-05-24

Halicin-loaded injectable hyaluronic acid hydrogel for ferroptosis-driven osteosarcoma therapy via Fe2+ accumulation.

Hu Xuyan X, Zhuang Hao H, Gao Ke K, Zhu Yaqi Y et al.

Osteosarcoma (OS) is the most common primary malignant bone tumor in adolescents, featuring aggressive tumor growth and early metastasis. Current treatments, including chemotherapy and surgery, are often limited by chemoresistance and postoperative infections. Ferroptosis has emerged as a strategy to overcome chemoresistance, as it is intrinsically iron-dependent, whereas OS often exhibits dysregulated iron metabolism. Halicin, a broad-spectrum antimicrobial known to regulate iron metabolism in bacteria, was found to be a ferroptosis inducer for OS in this study. However, its therapeutic efficacy is likely hampered by rapid systemic clearance and poor tumor retention. Accordingly, we developed Halicin@Gel, an injectable hyaluronic acid hydrogel designed for localized and prolonged release. The structure, injectability, drug release behavior, biocompatibility, antibacterial activity, and antitumor efficacy of this system were characterized and evaluated in vitro and in vivo. Halicin@Gel exhibited excellent antibacterial activity and significantly inhibited OS cell proliferation and migration in vitro. Mechanistically, Halicin@Gel increased intracellular ROS levels and was associated with p38 MAPK activation, as well as ferroptosis- and apoptosis-related changes. In vivo, Halicin@Gel significantly inhibited tumor growth with minimal systemic toxicity, confirming its therapeutic potential. Thus, these findings support Halicin@Gel as a promising localized therapeutic platform with combined antitumor and antibacterial functions for OS treatment.

PMID 42176915
Read full article →
PubMedTissue engineering. Part B, Reviews2026-05-24

Calcium Hydroxylapatite for Facial Rejuvenation: Properties, Mechanisms, and Clinical Applications.

Huang Yuling Y, Ma Xinrui X, Guo Jiasong J

Calcium hydroxylapatite (CaHA) has evolved from hard tissue applications to become a prospective bioactive filler for facial rejuvenation, offering both immediate volumization and long-term regenerative benefits. This review synthesizes literature up to 2025 to summarize the material properties, mechanisms of action, and clinical applications of CaHA-based fillers, evaluating their safety and efficacy. CaHA-based fillers provide structural support and stimulate collagen synthesis by activating fibroblasts, leading to sustained improvements in skin quality, volume restoration, and contour enhancement. Clinical evidence confirms the effectiveness of both pure CaHA and composite formulations combining CaHA with hyaluronic acid, which integrate rapid correction with prolonged regeneration. However, risks such as nodule formation, technical challenges, and the absence of reversal agents require consideration. CaHA-based fillers represent a significant advancement in minimally invasive facial rejuvenation by merging mechanical support with biological regeneration. Future research should focus on optimizing particle design, standardizing injection protocols, and developing multifunctional carriers to enhance safety and predictability.Impact StatementAs a traditional material for bone and dental repair, calcium hydroxylapatite (CaHA) has surprisingly emerged as a bioactive soft-tissue filler for facial rejuvenation. This review clarifies why this inorganic material can stimulate collagen, restore volume, and improve skin quality, bridging its regenerative mechanisms with clinical practice. By summarizing current applications, efficacy evidence, and safety considerations, we aim to enhance professional understanding, promote wider adoption, and inspire further translational research in minimally invasive aesthetic medicine.

PMID 42175763
Read full article →
PubMedOncogene2026-05-24

Lactic acid induces dendritic cell pyroptosis through MCT-1 to promote tumor immune evasion.

Yang Shengrui S, Lin Liyuan L, Zheng Xiang X, Li Jie J et al.

Elevated metabolites in the tumor microenvironment (TME), particularly lactic acid, create an immunosuppressive milieu that promotes immune escape and tumor progression. Dendritic cells (DCs) are pivotal in initiating and regulating immune responses against tumors. However, the impact of lactic acid on DC death in the TME remains unclear. Our study reveals that lactic acid induces dose-dependent pyroptosis of bone marrow-derived DCs (BMDCs) through GSDMD cleavage. Mechanistically, this process involves monocarboxylate transporter 1(MCT1)-mediated signaling via the K+/NLRP3/GSDMD axis, facilitating immune evasion and cancer progression. Furthermore, inhibiting MCT1 attenuated lactic acid-induced DC pyroptosis both in vitro and in vivo. These findings offer mechanistic insights into how lactic acid-mediated DC pyroptosis contributes to tumor immune evasion, suggesting potential targets for enhancing cancer therapies.

PMID 42177282
Read full article →
PubMedPoultry science2026-05-24

Dietary alpha‑lipoic acid, sprouted wheat, and multi‑enzyme supplementation improve yolk fatty acid profile and antioxidant status in laying hens.

Fazlollah Farbood F, Ghazanfari Shokoufe S, Sharifi Seyed Davood SD, Nobari Karim K et al.

In a completely randomized trial, we investigated the individual and combined effects of sprouted wheat (SW, 5%), a multi‑enzyme blend (ME; 500 mg/kg), and alpha‑lipoic acid (ALA; 300 mg/kg) on yolk fatty acid composition and cholesterol content, blood biochemical indices, and oxidative‑stress‑related parameters in SuperNick laying hens, using 10 dietary treatments (n = 200; five replicates of four hens each) over a 60‑day period. Experimental diets containing 5% wheat or wheat sprout produced only modest changes in dietary fatty acid composition, with all diets remaining high in polyunsaturated fatty acids (PUFA) and low in trans‑fatty acids. Wheat slightly improved the PUFA to saturated fatty acid (SFA) ratio and the proportion of long‑chain n‑3 PUFA, while both wheat and sprouted wheat marginally reduced the excessively high n‑6 to n‑3 and linoleic / alpha‑linolenic acid ratios compared with the corn‑based control. In egg yolk, dietary treatments significantly modified saturated, monounsaturated, and polyunsaturated fatty acid profiles (P < 0.001). Alpha‑lipoic acid was the main driver of changes in SFA, lowering total SFA primarily through reductions in palmitic, myristic, and heptadecanoic acids, and increasing very‑long‑chain SFA. Yolk monounsaturated fatty acids were also affected, with ALA decreasing palmitoleic and oleic acids but increasing erucic acid, whereas wheat form and ME exerted smaller, more specific effects such as increased nervonic acid with sprouted wheat. Polyunsaturated fatty acids, particularly linoleic, alpha‑linolenic, eicosapentaenoic, and docosahexaenoic acids, were enhanced by ALA, especially in corn + ALA and wheat + ME + ALA diets, resulting in improved yolk n‑3 content and n‑3 to n‑6 ratio. Blood metabolites and antioxidant indices were strongly influenced by diet (P < 0.001), with ALA consistently lowering total cholesterol and triglycerides, modifying lipoprotein fractions, increasing superoxide dismutase activity, and reducing malondialdehyde, while sprouted wheat and ME alone showed limited but favorable effects on lipid peroxidation. Overall, ALA supplementation, especially in combination with wheat‑based diets and ME, beneficially modulated yolk fatty acid profile and systemic oxidative status, with only minor alterations in basal dietary lipid composition.

PMID 42176580
Read full article →
PubMedBioresource technology2026-05-24

Identification of a thermotolerant strain of Aureobasidium melanogenum DA22 and functional analysis of Spt23 as a key transcriptional regulator in high-temperature polymalic acid fermentation.

Yang Yu Y, Dai Linbing L, Odoline Ndabacekure N, Li Fulin F et al.

Industrial application of Aureobasidium pullulans in organic acid production is limited by mesophilic characteristics under thermal stress. Physiological screening of 120 wild-type isolates identified a naturally robust strain, Aureobasidium melanogenum DA22, which maintained near-optimal growth and preserved 93.8% of its maximum polymalic acid titer (24.55 g/L, calculated as l-malic acid) at 35°C. To confer thermotolerance to a high-yield chassis, candidate thermoprotective genes-including heat shock proteins, antioxidant enzymes, and transcription factor-were identified from strain DA22. Overexpression of the membrane-associated transcription factor gene SPT23 increased cell growth by 20.0% and enhanced malic acid production by 37.7% (reaching 39.86 g/L) at 35°C in shake flasks. Scale-up batch fermentations in 5-L bioreactors achieved 56.08 g/L of l-malic acid at 35°C. In contrast, SPT23 deletion caused morphological defects and metabolic repression. RT-qPCR analysis and physiological indicators also indicated that SPT23 overexpression coordinately upregulated genes involved in lipid and ergosterol biosynthesis to maintain membrane integrity under thermal stress and elevated key enzymes in the reductive tricarboxylic cycle to redirect carbon flux toward polymalic acid synthesis. Engineering with Spt23 presents an effective synthetic biology strategy to construct a thermotolerant microbial cell factory suitable for organic acid production under industrial thermal-stress conditions.

PMID 42176819
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about hyaluronic acid